Incidental finding of an 11C-acetate PET-positive multiple myeloma

Lee, Sang Mi; Kim, Tae Sung; Lee, Jeong Won; Kwon, Ho Jang; Kim, Yong Il; Kang, Se Hun; Kim, Seok Ki

doi:10.1007/s12149-009-0325-6

Cited by 20 publications

(4 citation statements)

References 16 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been some reports comparing AC-PET and FDG-PET in the clinical examination of MM. In two single-case reports, AC-PET appeared to be more sensitive than FDG-PET in assessing the tumor burden and/or response to therapy 16 , 17 . In addition, there only two cohort studies have been published to date, which compared these two imaging methods for this disease.…”

Section: Discussionmentioning

confidence: 95%

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Chen

Zhu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The optimal method of tumor burden evaluation in newly diagnosed multiple myeloma (NDMM) is yet to be determined. This study aimed to compare the value of 11C-acetate positron-emission tomography (PET)/computed tomography (CT) (AC-PET and 18F-fluorodeoxyglucose PET/CT (FDG-PET) in the assessment of tumor burden in NDMM. This study evaluated 64 NDMM patients between February 2015 and July 2018. AC-PET and FDG-PET were used to assess myeloma lesions. The clinical data, imaging results, and their correlations were analyzed. Diffuse bone marrow uptake in AC-PET was significantly correlated with biomarkers for tumor burden, including serum hemoglobin (P = 0.020), M protein (P = 0.054), the percentage of bone marrow plasma cells (P < 0.001), and the Durie–Salmon stage of the disease (P = 0.007). The maximum standard uptake value (SUVmax) of focal lesions and high diffuse bone marrow uptake in AC-PET showed stronger correlations with high-risk disease (P = 0.017, P = 0.013) than those in FDG-PET. Moreover, the presence of diffuse bone marrow uptake, more than ten focal lesions, and an SUVmax of focal lesions of > 6.0 in AC-PET, but not in FDG-PET, predicted a higher probability of disease progression and shorter progression-free survival (P < 0.05). AC-PET outperformed FDG-PET in tumor burden evaluation and disease progression prediction in NDMM.

show abstract

Section: Discussionmentioning

confidence: 95%

11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Chen

Zhu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…As tumoral cells can synthesise membranes by metabolising acetate, [ 11 C]Acetate PET/CT has also been studied, demonstrating higher rates of detection than [ 18 F]FDG PET/CT [35]. Its utility, as in the case of choline, was initially discovered incidentally [36].…”

Section: Discussionmentioning

confidence: 99%

Multitracer PET/CT with [18F]Fluorodeoxiglucose and [18F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

Initial staging of patients diagnosed with multiple myeloma (MM) can lead to negative results using conventional diagnostic imaging workup, including [18F]Fluorodesoxiglucose ([18F]FDG) PET/CT. The aim of this prospective pilot study was to evaluate the diagnostic efficacy of [18F]Fluorocholine ([18F]FCH) PET/CT in the initial staging of MM patients who were candidates for autologous bone marrow transplant. Materials and Methods: The inclusion criteria of our study were: (a) patients diagnosed with MM; (b) candidates for autologous bone marrow transplant (AT); and (c) studied with [18F]FCH PET/CT and [18F]FDG PET/CT for initial staging less than 4 weeks apart. Imaging analysis included the presence of: bone marrow infiltration, focal bone lesions, and para-medullary or extra-medullary disease, according to the proposed IMPeTus criteria. The analysis was performed per lesion, per patient, and per location. Results: The study population included ten patients. Globally, [18F]FCH PET/CT showed bone marrow uptake in all the patients and visualised 16 more focal lesions than [18F]FDG PET/CT. One patient presented a plasmacytoma, detected by both tracers. Extra-medullary and para-medullary disease was identified with different degrees of uptake by both tracers. In summary, [18F]FCH PET seemed to be superior to [18F]FDG PET/CT in detecting focal bone lesions. SUVmax values were slightly higher in [18F]FCH PET/CT than in [18F]FDG PET/CT. Conclusions: Taking into account the small study population, according to our results, [18F]FCH PET/CT could be a useful tool for staging MM patients.

show abstract

“…The rate of 18 F-FLT uptake into lesions is directly proportional to DNA. Published data show that 18 F-FLT uptake is significantly increased in patients with myelodysplastic syndromes and myeloproliferative neoplasias [134]. There is intense uptake of 18 F-FLT in bone marrow and spleen (Fig.…”

Section: Imaging For Diagnosis and Staging Of Amlmentioning

confidence: 90%